Table 6. . Nanostructured lipid carriers fabricated using emulsification-sonication technique.
| Active ingredient | Solid lipid | Liquid lipid | Surfactants | Size (nm) | Research highlights | Ref. |
|---|---|---|---|---|---|---|
| Fenofibrate |
Precirol ATO 5 |
Captex 100 |
Tween 80 |
227.5 |
Fluid bed coating was found to be suitable method for solidification of NLCs without affecting their in vivo performance AUC values were improved after encapsulation in NLCs in comparison to marketed capsule |
[51] |
| Iloperidone |
Lauric acid |
Phosal® 53 MCT |
Tween 80, poloxamer 188 |
160 |
8.3-fold improvement in oral bioavailability of iloperidone after encapsulation in NLCs in comparison to drug suspension |
[52] |
| Montelukast |
Precirol® ATO 5 |
Capryol 90 |
D-L pyrrolidine carboxylic acid salt of l-cocyl arginine ethyl ester |
181.4 ± 6.5 |
Single oral dose of NLCs in rats provided 143-fold improvement in bioavailability in comparison to montelukast-aqueous solution |
[53] |
| Progesterone |
Stearic acid |
Oleic acid |
Tween 20 |
326.7 |
Sustained release of progesterone for 24 h was obtained |
[20] |
| Repaglinide | Precirol® ATO 5 | Caproyl 90 | Gelucire 50/13 | 170–210 | Novel stabilizer (Gelucire 50/13) was investigated for first time Higher antidiabetic action of repaglinide-loaded NLCs in comparison to commercial repaglinide tablets |
[54] |
AUC: Area under curve; NLC: Nanostructured lipid carrier.